Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts 282
Year : 2014  |  Volume : 5  |  Issue : 2  |  Page : 152-154

Fidaxomicin: A new fight against clostridium difficile-associated diarrhea

Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India

Correspondence Address:
Dick B. S. Brashier
Department of Pharmacology, Armed Forces Medical College, Pune - 411 013, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0975-9727.135753

Rights and Permissions

Clostridium difficile-associated diarrhea (CDAD) occurs commonly as a side effect of broad-spectrum antibiotics. Drugs approved for CDAD are only two of them, metronidazole and vancomycin. Most promising drug for treatment of CDAD is vancomycin, but due to emergence of hypervirulent strains, outcomes have become poor. Fidaxomicin has being approved lately for treatment of CDAD, which has shown good results as compared to vancomycin. Fidaxomicin inhibits protein synthesis by inhibiting transcription carried out by sigma subunit of RNA polymerase. Fidaxomicin has been seen to be a well tolerated, with minimal adverse effects. Clinical trials has showed that fidaxomicin has similar results to vancomycin in showing clinical response, whereas it was superior to vancomycin in having sustained clinical effect, in CDAD.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded282    
    Comments [Add]    

Recommend this journal